HC Wainwright Increases Insmed (NASDAQ:INSM) Price Target to $70.00
Insmed (NASDAQ:INSM – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $52.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 22.85% from the […]